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Abstract Proinflammatorycytokines Interleukin-1b (IL-1b) and Interleukin-6 (IL-6) playa significantroleinthepatho-
geneticprocessesrelatedtovariousmalignant andinflammatoryconditions.Leukocytosis, thrombocytosis andincreased
acutephase proteinlevels arepartof a systemic inflammatoryresponse.Inthis study, wemeasuredthe concentrations of
IL-1b, IL-6 and ferritin as well as hemoglobin, lactate dehydrogenase (LDH),C-reactive protein (CRP) and erythrocyte
sedimentationrate (ESR) in 23 patients (male15, female 8, median age 68 years) with lungcancer andreactive thrombo-
cytosis (LCRT), in 27 (male18, female 9, median age 64 years) withbenigninflammatorylungdisorder (BILD) and18 (male
10, female 8, median age 62 years) lungcancerpatientswith a normalplateletcount (LCNP).IL-1blevelswere significantly
higherinthethreepatientgroupsincomparisonwithcontrolsubjects (Po0.001) butwithout significantdifference among
the three patientgroups.IL-6 washigher in all three patientsgroupsbutonlyinthe BILD group itwas significantlyhigher
thanthe controlgroup (Po0.05).However, no significantdifferencein IL-6 serumlevelswas foundbetweenthetwolung
cancer groups.CRP and LDH were significantly higher in the LCRT group in comparison with the other two patient
groups (Po0.01and 0.001, respectively), while ferritinwashigher inbothlungcancergroupsin comparisonwiththeBILD
group (Po0.001).Ourdata suggestthat inlungcancerpatients, reactivethrombocytosisispartofthe systemicinflamma-
tory reaction for which IL-1band IL-6 may be intermediate but not independent mediators. r 2002 Elsevier Science Ltd. All
rights reserved.
doi:10.1053/rmed.2002.1328, available online at http://www.idealibrary.comon
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Reactive thrombocytosis is observed in a number of dis-
orders includingmalignancy, chronic in£ammatory or in-
fectious diseases and iron de¢ciency anemia (1). It has
been described in various malignancies including lung
cancer for which the reported incidence of thrombo-
cythemia is approximately 35^45% (2,3).
It is thought that reactive thrombocytosis may be the
result of a defect in the regulatorymechanism of platelet
production.Thismaybe caused by the excessive produc-
tion of hematopoietic growth factors that act on mega-
karyocytes in the bonemarrow resulting in an increased
platelet count in the periphery.The detection of the re-
sponsible mediators for reactive thrombocytosis hasReceived1August 2001, accepted in revised form 6March 2002.
Correspondence should be addressed to: Michael G. Alexandrakis,
Department of Haematology,University Hospital of Heraklion, P.O.
Box1352,Heraklion,Crete,Greece.Fax: +30 810 392425been the aim of several investigations and the results re-
ported implicate various cytokines, such as Interleukin-1
(IL-1), Interleukin-2 (IL-2), Interleukin-6 (IL-6),TNFa, and
growth factors, like thrombopoietin anderythropoietin,
in its pathogenesis (4^12). It is known that some of these
mediators also play an important role in in£ammation
(13,14). It would, therefore, seem that the thrombocyto-
tic response has common pathways in both malignancy
and in£ammation. However, the relative importance of
the common mediators in both conditions has not been
clari¢ed.
In this study, wemeasured the concentrations of IL1-b
and IL-6 in the serum of patients with lung cancer with
reactive thrombocytosis (LCRT) and patients with be-
nign in£ammatory lung diseases (BILDs) and compared
them with the serum concentrations in patients with
lung cancer with normal platelet counts (LCNP) and nor-
mal subjects in order to detect di¡erences in their con-
centrations.We alsomeasured in all subjects the levels of
554 RESPIRATORYMEDICINEhemoglobin, lactate dehydrogenase (LDH), C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR),
ferritin and the white blood cell count (WBC) as mar-
kers of disease activity.
Our hypothesis was that IL-1b, IL-6 and markers of
in£ammation would be elevated in the two groups
with lung cancer with reactive thrombocytosis and in-
£ammatory diseases in comparison with the other two
groups.
MATERIALSANDMETHODS
We examined 67 patients hospitalized in our institution
and prior to receiving any treatment.Of these patients,
23 (male15, female 8, median age 68 years) had LCRT, de-
¢ned by a rise in the platelet count of more than
400103/ml; 18 (male 10, female 8, median age 62 years)
had LCNP 150103^400103/ml; and 27 (male 18,
female 9, median age 64 years) had BILDs (Table 1). A
group of 25 healthy blood donors (male 14, female 11,
median age 39 years) was examined as controls.The di-
agnosis of malignancy or benign in£ammatory disease
was based on clinical examination, imaging techniques,
cytological and histological features.The clinical charac-
teristics of the patients examined are summarized in Ta-
ble 1. Informed consent was obtained from all the
subjects studied.
Serawere obtained from peripheral venous blood un-
der sterile conditions. For each sample, 3ml was added
into a sterile tube containing EDTA-K3 as an anti-coagu-
lant for cell counting, and in a second sterile tube10ml of
blood was allowed to clot for 30min and the serumwas
obtained by centrifugation at 3000 rpm for 20min.TABLE 1. Clinical characteristics of patients with LCRT,
LCNPand BILDs
Disease No. of
patients
Mean
age (years)
Sex (M/F)
LCRT
Squamous 4 66.7 4/0
Adenocarcinoma 10 63.7 5/5
Small cell 7 68.8 5/2
Large cell 2 63 2/0
LCNP
Squamous 4 66 3/1
Adenocarcinoma 10 63.1 5/3
Small cell 4 68 4/0
Large cell 0 F F
BILD
Pneumonia 16 61.3 13/3
Tuberculosis 6 68.5 5/1
Eosinophilic pneumonia 4 39.2 3/1
Rheumatoid Arthritis
with lung involvement
1 65 1/0Aliquots of the sera were stored at 701C until assay.
The blood analysis for hematocrit, hemoglobin and pla-
telet count was performed in an STKS Coulter cyt-
ometer (Electronics Inc., Florida, U.S.A.) on whole
venous blood drawn into EDTAK3 counting tubes. Ser-
um levels of IL-1b and IL-6 were determined immunora-
diometrically using the respective assay kits
commercially available from Amersham International,
U.K.This method is based on the competition between
unlabelled cytokine and a ¢xed quantity of 125I-labelled
recombinant cytokine for a limited number of binding
sites on cytokine-speci¢c antibodies, according to the
manufacturers’ method. C-reactive protein was deter-
minedby nephelometry (Kallestad,QM 300 Sano¢ Diag-
nostics Pasteur Inc,MN,U.S.A.).
Serum ferritin levels were assessed by an immunora-
diometric assay kit (Amersham Int, U.K.) and serum
LDH was measured using a commercially available kit
supplied by Olympus System Reagent 500 (Olympus Di-
agnostics GmbH Co, Clare, Ireland). The ESR was mea-
sured by the Westergren method. Samples were
obtainedbefore any therapy was instituted.
Statistical analysis
Results are expressed as means7standard error of the
mean, unless otherwise indicated.Between groups com-
parisonwas performedusing ANOVA.The Pearson cor-
relation coe⁄cientbetween all parameters and IL-1band
IL-6 was estimated.Results were considered statistically
signi¢cant if P values wereo0.05.
RESULTS
IL-1b levels were signi¢cantly higher in the three patient
groups (LCRT, LCNP and BILD) in comparison with nor-
mal subjects (Po0.001^0.05) (Fig. 1). However, IL-b was
not signi¢cantly di¡erent in lung cancer patientswith re-
active thrombocytosis in comparison with lung cancer
patients with normal platelet counts and patients with
benign in£ammatory lung diseases (P40.05) (Table 2).
IL-6 was higher in all the three patient groups but only
in the BILD group it was signi¢cantly higher than the
control group (Po0.05, Fig. 2). Furthermore, there was
no signi¢cant di¡erence between the two lung cancer
groups (Table 2).
Hemoglobin was signi¢cantly lower in LCRT group in
comparison with BILD (Po0.05). WBC count was also
signi¢cantly higher in LCRT group in comparison with
the other two patient groups (Po0.001 both). The ESR
was signi¢cantly lower in the BILD group in comparison
with the other two groups of patients (Po0.001 both).
CRP was signi¢cantly higher in the LCRT group in com-
parison with the other two groups of patients (Po0.01
both), and ferritinwas higher in both lung cancer groups
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FIG. 1. Mean (SEM) IL-1blevels in the three studiedgroups of patients (LCRT,LCNPand BILD) and the controlgroup.
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FIG. 2. Mean (SEM) IL-6 levels in the three studiedgroups of patients (LCRT,LCNPand BILD) and the controlgroup.
LUNGCANCERWITHTHROMBOCYTOSIS 555in comparison with BILD (Po0.001 both). LDH was
also signi¢cantly increased in the LCRT group in
comparison with both the other groups of patients
(Po0.001both).
There was a signi¢cant negative correlation between
IL-1b levels and ESR in the LCRT group (r=0.47,Po0.02)
(Fig. 3). In addition, there was a positive correlation be-
tween IL-1b and ESR in the LCNP group (r= 0.49,
Po0.04) (Fig. 4). Furthermore, IL-1b levels correlated
positively with CRP levels (r= 0.45, Po0.02) in the BILD
group (Fig. 5).No correlationwas foundbetween thepla-
telet count and serum IL-1bor IL-6 levels.DISCUSSION
In this study, we found thatpatientswith lung cancer and
reactive thrombocytosis have increased levels of IL-1b in
comparisonwith thosewith lung cancer and normal pla-
telets, those with benign in£ammatory lung diseases as
well as with the normal control group.This was not true
regarding the IL-6 levels in the same groups, but there
was a trend to be higher in patients with benign in£am-
matory lung diseases.
Reactive thrombocytosis occurring as a paraneo-
plastic syndrome has been described extensively in the
TABLE 2. Mean (SEM) concentrations of hematological and biochemical parameters measured in the patient groups with LCRT,
LCNP, and BILDandnormal controls
Variable LCRT LCNP BILD Controls
Hct (%) 33.871.2a 36.871.3 38.670.8 44.573.0
Hb (g/dl) 11.470.4a 12.370.4 12.970.2 14.871.1
WBC (103/ml) 14.971.2b 8.3870.26 10.670.5 7.2570.23
PLT (103/ml) 642736b 219711 21177 22370.04
ESR (mm/1h) 10375 87.476.7 63.575.8c 9.6472.20
LDH (IU/l) 447764b 300740 208717 159734
CRP (mg/dl) 7.7071.18b 4.1270.95 3.4970.50 0.33670.150
Ferritin (ng/ml) 637782 6327130 242727c 49.2727.5
aLCRT group in comparisonwith BILD, Po0.05.
bLCRT group in comparisonto LCNPand BILD, Po0.001.
cBILD group in comparisonto LCRTand LCNP, Po0.001.
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FIG. 3. Correlation between IL-1blevels and ESR in the group
of patientswith lungcancer andreactive thrombocytosis.
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FIG. 4. Correlation between IL-1blevels and ESR in the group
of patientswith lungcancer andnormalplateletcount.
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FIG. 5. Correlationbetween IL-1blevels and CRPinthe group
of patientswith benign in£ammatorylungdiseases.
556 RESPIRATORYMEDICINEliterature. In large observational studies, it has been de-
termined as an independent factor of poor prognosis in
malignancies (2,15).Furthermore, its incidence is high re-
ferred to as 45% in cases of non-small cell lung cancer and
35% of small cell lung cancer (2,3). However, the patho-
physiology of reactive thrombocytosis remains unclear.
It is suggested that humoral factors such as IL-6, IL-1b,
G-CSF and GM-CSF produced bymalignant cells may be
involved (16).
Up till now, studies have failed to elucidate the exact
role of IL-6 in reactive thrombocytosis in lung cancer
and have come to con£icting results.Yanagawa et al. (17)
described increased IL-6 levels in the serum of patients
with lung cancer. The group of patients with increased
serum IL-6 had increased acute phase proteins in com-
parison with lung cancer patients with undetectable
IL-6. They concluded that IL-6 induces the systemic
LUNGCANCERWITHTHROMBOCYTOSIS 557in£ammatory response in patients with lung cancer.
However, the platelet count was not increased in pa-
tients with high IL-6 (17). To the contrary, there is evi-
dence that IL-6 is implicated in reactive thrombocytosis
of cancer (11,18).This has been extensively studied in rela-
tion to reactive thrombocytosis observed in malignant
mesothelioma (19,20) and renal cell carcinoma (14,21).
Furthermore, increased levels of IL-6 have been shown
to be an independent poor prognostic factor in lung
carcinoma (22, 23). Our results are in agreement with
Yanagawa et al. (17) as CRP and ferritin were found
increased in the LCRT group, but not IL-6. However,
in our study we included a group with benign in£amma-
tory lung diseases to compare the in£ammatory re-
sponse. In the BILD group, IL-6 was not signi¢cantly
increased relative to both lung cancer groups and con-
trols but the platelets were normal.One interpretation
of this could be that, although it is has been uniformly
shown that IL-6 levels are high in malignant states,
it induces the in£ammatory response and increases the
hepatic synthesis of reactive proteins (3, 23) but has
a smaller e¡ect on thrombopoiesis for which it is
not the main mediator. IL-6 production, as a marker of
in£ammatory response, is more pronounced in the
host’s response to bacterial stimuli in comparison with
neoplastic cells. This is in agreement with a previous
report where IL-6 was found higher in tuberculous in
comparison with malignant pleural e¡usions (24). How-
ever, it must be noted that although the results of the
statistical analysis failed to show any signi¢cance, there
was an increasing trend in IL-6 concentrations in lung
cancer patientswithreactive thrombocytosis in compar-
ison with lung cancer patients with normal platelet
counts and normal population (mean IL-6 serum levels
0.739 vs 0.686 and 0.307 fmol/ml, respectively). This
could be explained by the assumption that IL-6 levels
may have been increased at a time prior to the study
and at a time of clinical evidence of cancer, being bound
with IL-6 receptors and exerting bone marrow in£u-
ence. This has been implied in a study where IL-6 was
found increased in the pleural e¡usion but not in the
serum of patients with carcinomatous pleurisy (25).
Alternatively, the increase in serum IL-6 may be a late
event in the clinical course ofmalignancy andnotdirectly
connected with thrombocytosis. This is suggested
by a published case report of mesothelioma where the
platelet count rose in parallel with increasing levels
of IL-6 as the disease advanced (19) and by the positive
correlation of increased levels of IL-6 in advanced lung
cancer disease (23).
The other cytokine measured, IL-1, has not been
studied, to our knowledge, in relation to thrombocytosis
in lung cancer. In a study in lung cancer patients, IL-1
was found lower in comparison with normal controls
(23). In another study of IL-1 concentrations in pleural
e¡usions, it was found low in both malignant andin£ammatory exudates showing no discriminatory value
between the two diseases (26). This is in disagreement
with our study where IL-1b was found signi¢cantly in-
creased in patients with LCRT, LCNP and BILD in com-
parison with normal population. IL-1b has been
characterized as one of the mediators of the in£amma-
tory response with an essential role in T-cell activation
and is producedbymany types of cells, mainlymononuc-
lear phagocytes, in response to in£ammatory stimuli
(27). IL-1exerts awide range of actions, including regula-
tion of thrombopoiesis (5,28).
High IL-1 and IL-6 levels have been described in the
plasma and culture supernatants of tumor cells from pa-
tients with tumor-producing colony-stimulating factor
(18). IL-1 in combinationwith IL-4 has been found to aug-
ment megakaryocyte colony formation (29). This evi-
dence supports our clinical ¢ndings that lung cancer
patients with thrombocytosis exhibit signi¢cantly
higher serum IL-1blevels in comparisonwithnormal con-
trols. However, the attribution of thrombocytosis to
IL-1b is weak as high levels were also found in lung cancer
and lung in£ammation patients with normal platelet
counts. Therefore, it seems that IL-1b is a common
mediator of in£ammation both in benign and malignant
diseases but is not themainmediator of reactive throm-
bocytosis.
From the comparison of the routine hematological
and biochemical measurements, it was evident that the
LCRT group exhibited an augmented in£ammatory re-
sponse. Not only were the platelets increased, but also
thewhiteblood cellswere signi¢cantly higher in compar-
ison with the other groups, showing a proliferative re-
sponse of the white blood cell and megakaryocyte
series.On the other hand, anemia was a prominent fea-
ture of this group, whichmaybe due to thepresence of a
depressant of hemopoiesis or increased blood loss.Our
¢ndings are in accordance with other studies where the
coexistence of thrombocytosis with elevated WBC and
anemia in cancer patients was attributed to the desensi-
tization to body erythropoietin in the presence of IL-6
(14,16,17). Furthermore, CRP, an in£ammatory marker,
was higher in the LCRT group in comparison with all
others. LDH was also signi¢cantly higher in the same
group and indicated the level of disease activity. It has
been shown that LDH is an independent prognostic fac-
tor in lung cancer (15), so higher levels in the reactive
thrombocytosis group indicates the increased severity
of the disease in this group.
We therefore conclude that in lung cancer patients,
reactive thrombocytosis is part of the systemic in£am-
matory response syndrome for which IL-1b and IL-6
may be intermediate but not independent mediators.
Further investigations are needed which will be
useful not only to elucidate the bone marrow^tumor
interaction but also to improve the therapeutical man-
agement of cancer patients.
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